June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Feasibility of TGF-β inhibition for the treatment of Fuchs endothelial corneal dystrophy
Author Affiliations & Notes
  • Naoki Okumura
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Keisuke Hashimoto
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Hirokazu Okuda
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Emi Ueda
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Theofilos Tourtas
    Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • Ursula Schlotzer-Schrehardt
    Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • Friedrich E Kruse
    Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • Noriko Koizumi
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Footnotes
    Commercial Relationships   Naoki Okumura, Doshisha University (P), Senju Pharmaceutical Co. (P); Keisuke Hashimoto, None; Hirokazu Okuda, None; Emi Ueda, None; Theofilos Tourtas, None; Ursula Schlotzer-Schrehardt, None; Friedrich Kruse, None; Noriko Koizumi, Doshisha University (P), Senju Pharmaceutical Co. (P)
  • Footnotes
    Support   Program for the Strategic Research Foundation at Private Universities from MEXT (Koizumi N and Okumura N).
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1434. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Naoki Okumura, Keisuke Hashimoto, Hirokazu Okuda, Emi Ueda, Theofilos Tourtas, Ursula Schlotzer-Schrehardt, Friedrich E Kruse, Noriko Koizumi; Feasibility of TGF-β inhibition for the treatment of Fuchs endothelial corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1434.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Endoplasmic reticulum (ER) stress is thought to be involved in the pathophysiology of Fuchs endothelial corneal dystrophy (FECD). We reported that the corneal endothelium in FECD is hyper responsive to TGF-β, resulting in excessive extracellular matrix (ECM) production. In this study, we investigated whether TGF-β signaling causes ER stress and evaluated the feasibility of TGF-β signaling as a therapeutic target of FECD.

Methods : Descemet’s membrane including corneal endothelial cells (CEC) were obtained from 30 patients during Descemet’s membrane endothelial keratoplasty (DMEK), and from 30 donor corneas as a control. TGF-β1, TGF-β2, TGFβR1, and TGFβR2 expression was evaluated by RT-PCR. As cellular models, CEC were isolated from 3 FECD-patient corneas and 3 donor corneas, then cultured and immortalized (henceforth: iFECD and iHCEC). ECM proteins fibronectin and collagen type 1, ER stress sensors ATF6, IRE1, and PERK, and apoptosis related proteins CHOP, caspase3, and PARP were examined by western blotting. Unfolded protein was evaluated by aggresome staining. SB431542, TGFβR1 siRNA, and Smad3 inhibitor was used to evaluate the effect of inhibiting TGF-β signaling on ER-stress-mediated apoptosis. Mitochondrial membrane potential was evaluated by flow cytometry.

Results : RT-PCR demonstrated that TGF-β1, TGF-β2, TGFβR1, and TGFβR2 expression was significantly higher in FECD-patient corneal endothelium than in controls (p<0.01). In cell models, TGF-β2 induced production of ECM proteins and activation of PERK and CHOP at a higher level in iFECD than in iHCEC. In iFECD, SB431542, TGFβR1 siRNA, and Smad3 inhibitor suppressed expression of fibronectin and formation of unfolded protein. ATF6, IRE1, and PERK were activated in iFECD, but SB431542 downregulated activation of those sensor proteins. Flow cytometry showed that SB431542 significantly suppressed the percentage of mitochondrial membrane demoralized cells (p<0.01). Consistently, cleavage of caspase 3 (apoptosis executor molecule) and PARP was suppressed by SB431542.

Conclusions : The expression level of TGF-β isoforms and TGF-β receptors is high in FECD-patient corneal endothelium, which maybe induces high responsiveness to TGF-β and leads to ER stress. Inhibition of TGF-β signaling might be a therapeutic target by suppressing ER-stress-mediated cell death as well as accumulation of ECM of FECD.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×